Glenmark Life Sciences will manufacture API in the therapeutic area of urinary anti-spasmodic, to supply to the global innovator
Liraglutide belongs to the class of glucagon like peptide 1 receptor agonist (GLP?1 RA) drugs
European operations' revenue grew 58.4% to Rs 599.7 crore
Glenmark's Zita portfolio of medicines have been benefiting around 1.75 million Type 2 diabetic patients annually
Glenmark's current portfolio consists of 188 products authorized for distribution in the US
Glenmark will receive from Cassiopea, a subsidiary of Cosmo, the exclusive right to commercialize Winlevi in 15 EU countries
Will continue to own a 7.84 per cent stake in Glenmark Life Sciences with the stake reduction
The company has entered into a three-year Deferred Prosecution Agreement
Glenmark's current portfolio consists of 184 products authorized for distribution in the U.S. marketplace
The net profit in the June quarter was also lower than Rs 146.3 crore reported in the March quarter.
Subscribe To Our Newsletter & Stay Updated
